Perioperative Allogenenic Blood Transfusion Is Associated with Worse Clinical Outcomes for Hepatocellular Carcinoma: A Meta-Analysis

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Liu, Lei ^a   Wang, Zhiwei ^b   Jiang, Songqi ^a   Shao, Bingfeng ^a   Liu, Jibing ^a   Zhang, Suqing ^a   Zhou, Yilong ^a   Zhou, Yuan ^a   Zhang, Yixin ^a  

^a NANTONG UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLOOD TRANSFUSION; CANCER MORTALITY; CAUSE OF DEATH; DISEASE ASSOCIATION; HUMAN; LIVER CELL CARCINOMA; META ANALYSIS; OUTCOMES RESEARCH; PERIOPERATIVE PERIOD; POSTOPERATIVE COMPLICATION; RISK ASSESSMENT; SYSTEMATIC REVIEW; TUMOR RECURRENCE;

AGED; ALLOGRAFTS; BLOOD TRANSFUSION; CARCINOMA, HEPATOCELLULAR; DATABASES, BIBLIOGRAPHIC; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PERIOPERATIVE CARE; RECURRENCE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84878596838     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064261     Document Type: Article

References (50)

1. Venook AP, Papandreou C, Furuse J, de Guevara LL, (2010) The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 15Suppl 4: 5-13.
2. Wall WJ, Marotta PJ, (2000) Surgery and transplantation for hepatocellular cancer. Liver Transpl 6: S16-22.
3. Poon RT, Fan ST, Lo CM, Liu CL, Lam CM, et al. (2004) Improving perioperative outcome expands the role of hepatectomy in management of benign and malignant hepatobiliary diseases: analysis of 1222 consecutive patients from a prospective database. Ann Surg 240: 698-708; discussion 708-610.
4. Cescon M, Vetrone G, Grazi GL, Ramacciato G, Ercolani G, et al. (2009) Trends in perioperative outcome after hepatic resection: analysis of 1500 consecutive unselected cases over 20 years. Ann Surg 249: 995-1002.
5. Marcucci C, Madjdpour C, Spahn DR, (2004) Allogeneic blood transfusions: benefit, risks and clinical indications in countries with a low or high human development index. Br Med Bull 70: 15-28.
6. Domen RE, Hoeltge GA, (2003) Allergic transfusion reactions: an evaluation of 273 consecutive reactions. Arch Pathol Lab Med 127: 316-320.
7. Nielsen HJ, (1995) Detrimental effects of perioperative blood transfusion. Br J Surg 82: 582-587.
8. Hanazaki K, Kajikawa S, Shimozawa N, Matsushita A, Machida T, et al. (2005) Perioperative blood transfusion and survival following curative hepatic resection for hepatocellular carcinoma. Hepatogastroenterology 52: 524-529.
9. Kwon AH, Matsui Y, Kamiyama Y, (2001) Perioperative blood transfusion in hepatocellular carcinomas: influence of immunologic profile and recurrence free survival. Cancer 91: 771-778.
10. Sauerland S, Seiler CM, (2005) Role of systematic reviews and meta-analysis in evidence-based medicine. World J Surg 29: 582-587.
11. Akobeng AK, (2005) Understanding systematic reviews and meta-analysis. Arch Dis Child 90: 845-848.
12. Moher D, Liberati A, Tetzlaff J, Altman DG, (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 62: 1006-1012.
13. Leucht S, Kissling W, Davis JM, (2009) How to read and understand and use systematic reviews and meta-analyses. Acta Psychiatr Scand 119: 443-450.
14. Mak A, Cheung MW, Fu EH, Ho RC, (2010) Meta-analysis in medicine: an introduction. Int J Rheum Dis 13: 101-104.
15. Higgins JP, Thompson SG, Deeks JJ, Altman DG, (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-560.
16. Sutton AJ, Duval SJ, Tweedie RL, Abrams KR, Jones DR, (2000) Empirical assessment of effect of publication bias on meta-analyses. BMJ 320: 1574-1577.
17. Matsumata T, Ikeda Y, Hayashi H, Kamakura T, Taketomi A, et al. (1993) The association between transfusion and cancer-free survival after curative resection for hepatocellular carcinoma. Cancer 72: 1866-1871.
18. Itasaka H, Yamamoto K, Taketomi A, Higashi H, Kamakura T, et al. (1995) Influence of blood transfusion on postoperative long-term liver function in patients with hepatocellular carcinoma. Hepatogastroenterology 42: 465-468.
19. Yamamoto J, Kosuge T, Takayama T, Shimada K, Yamasaki S, et al. (1996) Recurrence of hepatocellular carcinoma after surgery. Br J Surg 83: 1219-1222.
20. Asahara T, Katayama K, Itamoto T, Yano M, Hino H, et al. (1999) Perioperative blood transfusion as a prognostic indicator in patients with hepatocellular carcinoma. World J Surg 23: 676-680.
21. Makino Y, Yamanoi A, Kimoto T, El-Assal ON, Kohno H, et al. (2000) The influence of perioperative blood transfusion on intrahepatic recurrence after curative resection of hepatocellular carcinoma. Am J Gastroenterol 95: 1294-1300.
22. Kitagawa K, Taniguchi H, Mugitani T, Koh T, Obayashi T, et al. (2001) Safety and advantage of perioperative autologous blood transfusion in hepatic resection for hepatocellular carcinoma. Anticancer Res 21: 3663-3667.
23. Ercolani G, Grazi GL, Ravaioli M, Del Gaudio M, Gardini A, et al. (2003) Liver resection for hepatocellular carcinoma on cirrhosis: univariate and multivariate analysis of risk factors for intrahepatic recurrence. Ann Surg 237: 536-543.
24. Sasaki Y, Yamamura H, Kawakami Y, Yamada T, Hiratsuka M, et al. (2002) Expression of smooth muscle calponin in tumor vessels of human hepatocellular carcinoma and its possible association with prognosis. Cancer 94: 1777-1786.
25. Wei AC, Tung-Ping Poon R, Fan ST, Wong J, (2003) Risk factors for perioperative morbidity and mortality after extended hepatectomy for hepatocellular carcinoma. Br J Surg 90: 33-41.
26. Laurent C, Blanc JF, Nobili S, Sa Cunha A, le Bail B, et al. (2005) Prognostic factors and longterm survival after hepatic resection for hepatocellular carcinoma originating from noncirrhotic liver. J Am Coll Surg 201: 656-662.
27. Sasaki Y, Yamada T, Tanaka H, Ohigashi H, Eguchi H, et al. (2006) Risk of recurrence in a long-term follow-up after surgery in 417 patients with hepatitis B- or hepatitis C-related hepatocellular carcinoma. Ann Surg 244: 771-780.
28. Sugita S, Sasaki A, Iwaki K, Uchida H, Kai S, et al. (2008) Prognosis and postoperative lymphocyte count in patients with hepatocellular carcinoma who received intraoperative allogenic blood transfusion: a retrospective study. Eur J Surg Oncol 34: 339-345.
29. Kaibori M, Saito T, Matsui K, Yamaoka M, Kamiyama Y, (2008) Impact of fresh frozen plasma on hepatectomy for hepatocellular carcinoma. Anticancer Res 28: 1749-1755.
30. Wang CC, Iyer SG, Low JK, Lin CY, Wang SH, et al. (2009) Perioperative factors affecting long-term outcomes of 473 consecutive patients undergoing hepatectomy for hepatocellular carcinoma. Ann Surg Oncol 16: 1832-1842.
31. Choi GH, Kim DH, Choi SB, Kang CM, Kim KS, et al. (2009) The preoperative positivity for serum hepatitis B e antigen did not affect overall survival after curative resection of hepatitis B virus-related hepatocellular carcinoma. J Gastroenterol Hepatol 24: 391-398.
32. Abdel-Wahab M, El-Husseiny TS, El Hanafy E, El Shobary M, Hamdy E, (2010) Prognostic factors affecting survival and recurrence after hepatic resection for hepatocellular carcinoma in cirrhotic liver. Langenbecks Arch Surg 395: 625-632.
33. Nanashima A, Abo T, Hamasaki K, Wakata K, Tominaga T, et al. (2011) Perioperative non-tumorous factors associated with survival in HCC patients who underwent hepatectomy. Anticancer Res 31: 4545-4551.
34. Okamura Y, Takeda S, Fujii T, Sugimoto H, Nomoto S, et al. (2011) Prognostic significance of postoperative complications after hepatectomy for hepatocellular carcinoma. J Surg Oncol 104: 814-821.
35. Yang T, Zhang J, Lu JH, Yang GS, Wu MC, et al. (2011) Risk factors influencing postoperative outcomes of major hepatic resection of hepatocellular carcinoma for patients with underlying liver diseases. World J Surg 35: 2073-2082.
36. Kuroda S, Tashiro H, Kobayashi T, Oshita A, Amano H, et al. (2012) No impact of perioperative blood transfusion on recurrence of hepatocellular carcinoma after hepatectomy. World J Surg 36: 651-658.
37. Acheson AG, Brookes MJ, Spahn DR, (2012) Effects of allogeneic red blood cell transfusions on clinical outcomes in patients undergoing colorectal cancer surgery: a systematic review and meta-analysis. Ann Surg 256: 235-244.
38. Yao HS, Wang Q, Wang WJ, Hu ZQ, (2008) Intraoperative allogeneic red blood cell transfusion in ampullary cancer outcome after curative pancreatoduodenectomy: a clinical study and meta-analysis. World J Surg 32: 2038-2046.
39. Brunson ME, Alexander JW, (1990) Mechanisms of transfusion-induced immunosuppression. Transfusion 30: 651-658.
40. Blajchman MA, (1998) Immunomodulatory effects of allogeneic blood transfusions: clinical manifestations and mechanisms. Vox Sang 74Suppl 2: 315-319.
41. Vamvakas EC, Blajchman MA, (2007) Transfusion-related immunomodulation (TRIM): an update. Blood Rev 21: 327-348.
42. Ydy LR, Slhessarenko N, de Aguilar-Nascimento JE, (2007) Effect of perioperative allogeneic red blood cell transfusion on the immune-inflammatory response after colorectal cancer resection. World J Surg 31: 2044-2051.
43. Chen G, Zhang FJ, Gong M, Yan M, (2007) Effect of perioperative autologous versus allogeneic blood transfusion on the immune system in gastric cancer patients. J Zhejiang Univ Sci B 8: 560-565.
44. Ghio M, Contini P, Mazzei C, Brenci S, Barberis G, et al. (1999) Soluble HLA class I, HLA class II, and Fas ligand in blood components: a possible key to explain the immunomodulatory effects of allogeneic blood transfusions. Blood 93: 1770-1777.
45. Puppo F, Contini P, Ghio M, Brenci S, Scudeletti M, et al. (2000) Soluble human MHC class I molecules induce soluble Fas ligand secretion and trigger apoptosis in activated CD8(+) Fas (CD95)(+) T lymphocytes. Int Immunol 12: 195-203.
46. Puppo F, Ghio M, Contini P, Mazzei C, Indiveri F, (2001) Fas, Fas ligand,and transfusion immunomodulation. Transfusion 41: 416-418.
47. Ho WH, Lee KT, Chen HY, Ho TW, Chiu HC, (2012) Disease-free survival after hepatic resection in hepatocellular carcinoma patients: a prediction approach using artificial neural network. PLoS One 7: e29179.
48. Huang J, Li BK, Chen GH, Li JQ, Zhang YQ, et al. (2009) Long-term outcomes and prognostic factors of elderly patients with hepatocellular carcinoma undergoing hepatectomy. J Gastrointest Surg 13: 1627-1635.
49. Peng BG, He Q, Li JP, Zhou F, (2009) Adjuvant transcatheter arterial chemoembolization improves efficacy of hepatectomy for patients with hepatocellular carcinoma and portal vein tumor thrombus. Am J Surg 198: 313-318.
50. Mathurin P, Raynard B, Dharancy S, Kirzin S, Fallik D, et al. (2003) Meta-analysis: evaluation of adjuvant therapy after curative liver resection for hepatocellular carcinoma. Aliment Pharmacol Ther 17: 1247-1261.